Quallent Pharmaceuticals Health LLCUsage: Adalimumab-ryvk is indicated for the treatment of moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in patients ages 2 and older.